This study aimed to evaluate the correlation between plasma adiponectin levels and plasma lipid and lipoprotein levels in post-menopausal women (PMW) receiving hormone replacement therapy (HRT). Various clinical and biochemical parameters, including plasma lipid and lipoprotein concentrations and adiponectin levels, were measured in 54 healthy PMW before and after 3 and 6 months of HRT. Control groups consisted of women aged < 40 years (n = 20) or > 60 years (n = 17). PMW had significantly lower baseline adiponectin levels compared with the younger or older control groups, but adiponectin concentrations were not significantly altered after 3 or 6 months of HRT. Adiponectin levels in PMW were positively correlated with plasma high-density lipoprotein-cholesterol levels and were negatively correlated with body mass index and triglyceride levels. Our data suggest that circulating adiponectin may contribute to lipid homeostasis in PMW. Further studies are needed to elucidate the effects of HRT and oestrogen on adiponectin levels.
Introduction
It has been well established that the incidence of cardiovascular disease increases after the onset of menopause. 1 The changes in lipid levels associated with hormone replacement therapy (HRT) were not predictive of coronary heart disease outcomes in women with heart disease in the Heart and Estrogen/progestin Replacement Study, however. 2 The adipocyte-derived plasma protein adiponectin is the most abundant gene product in adipose tissue. 3 It accounts for 0.01% of the total plasma protein and has been reported to decrease in obese individuals. 4 It has been shown to inhibit tumour necrosis factor-β-induced expression of endothelial adhesion molecules; 5 plasma adiponectin concentrations were also significantly lower in patients with coronary artery disease (CAD) compared with ageand body mass index-adjusted control subjects. 5 This suggests that decreased plasma adiponectin levels may be associated with the development of CAD through endothelial dysfunction. Overall, the measurement of plasma adiponectin concentrations seems to be beneficial in assessing the risk of CAD, although a prospective study is necessary to clarify the relationship between the development of CAD and reduced levels of plasma adiponectin.
Adiponectin has been reported to act as an endogenous biologically relevant modulator of endothelial cell responses to proinflammatory stimuli through cross-talk between cyclic AMP-protein kinase A and nuclear factor-κB signalling pathways. 6 In addition, it has been shown to reduce lipid accumulation in human monocyte-derived macrophages and act as a modulator for foaming macrophage formation, thus providing a basic mechanism for the linkage between overnutrition and atherosclerosis. 7 The correlation between blood adiponectin and lipid and lipoprotein levels in post-menopausal women (PMW) has not been previously investigated to our knowledge. This study was designed to evaluate this correlation and the effects of HRT on adiponectin and lipid and lipoprotein concentrations in blood. The levels of leptin, a protein known to be involved in the regulation of body weight, were also measured.
Patients and methods

PATIENTS
Post-menopausal women with climacteric syndrome and without evidence of gynaecological disorders were voluntarily enrolled into this study at the Cardiovascular Hospital of Central Japan, Gunma, Japan. All participants were healthy and ambulatory, and had been amenorrhoeic for at least 1 year or had a 17β-oestradiol plasma level of < 40 pg/ml and a plasma follicle-stimulating hormone (FSH) level of > 30 mIU/ml. In addition, they had not received HRT in the 3 months preceding enrolment. Patients were requested to maintain their usual exercise habits and diet, and were instructed not to take any over-the-counter medication during the study.
Two control groups consisting of women aged < 40 years who were pre-menopausal and not taking HRT and those aged > 60 years who were post-menopausal and not taking HRT were also recruited.
The study protocol was approved by the Institutional Committee on Human Research of the Cardiovascular Hospital of Central Japan. Written informed consent was obtained from all study participants.
PROTOCOL
All patients received continuous combined HRT consisting of 0.625 mg conjugated equine oestrogen (Asahi Kasei Co-operation, Osaka, Japan) and 2.5 mg medroxyprogesterone acetate (Sumitomo Pharmaceuticals, Tokyo, Japan) orally daily for 6 months.
Body weight, height, body mass index (BMI) and percentage fat distribution were measured, blood samples were taken and a physical examination performed at baseline and after 3 and 6 months of HRT. All blood specimens were taken in the morning after a 12 h fast period. The samples were stored at -80°C until analysis.
Subjects in the control groups did not receive HRT. Body weight, BMI, oestradiol, triglyceride (TG), high-density lipoprotein (HDL)-cholesterol and plasma adiponectin concentrations were measured in these women.
LABORATORY TESTS
Peripheral blood total cholesterol, TG, HDLand low-density lipoprotein (LDL)-cholesterol, oestrone, 17β-oestradiol, luteinizing hormone (LH) and FSH levels were measured at Medca Japan Co. Ltd (Konosu, Saitama, Japan) using enzymatic methods.
Adiponectin levels were measured in plasma samples with an enzyme-linked immunosorbent assay (ELISA) method, using a monoclonal antibody specific for adiponectin (LINCO Research Inc., St. Charles, Missouri, USA) pre-coated onto a microtitre plate. An enzyme-linked polyclonal antibody specific for leptin was used as the second antibody (Jimro Co. Ltd, Takasaki, Japan).
The plasma concentration of leptin (ng/ml) was measured using a commercially available kit based on the radioimmunoenzymatic assay (LINCO Research Inc.). Within and between assay variations were 4.98% and 4.5%, respectively, and the limit of sensitivity was 0.5 ng/ml.
STATISTICAL ANALYSES
Data were expressed as the mean ± SD and were analysed using the unpaired Student's t-test. The associations between plasma adiponectin or leptin and the various parameters measured were evaluated using linear regression analysis. A P-value of < 0.05 was considered to be statistically significant.
Results
Fifty-four healthy PMW with a mean ± SD age of 58 ± 6 years (range 46 -66 years) were included in the study. The control groups consisted of 20 women aged < 40 years and 17 women aged > 60 years.
The ELISA kit used for the measurement of plasma adiponectin levels was shown to have a sensitivity of 0.96 µg/ml, intra-assay variation of 3.5 -4.5%, an inter-assay coefficient of 0.964, and no cross-reactivity for sera from animals.
The variable characteristics measured in the enrolled PMW population are given in Table 1 . After 3 and 6 months' treatment with HRT, no significant changes were found in blood pressure or heart rate compared with those at baseline (data not shown). Statistically significant elevations in plasma oestrone and 17β-oestradiol levels and reductions in the LH and FSH concentrations were observed after 3 and 6 months, whereas body weight, height and percentage fat distribution did not show any significant changes. With regards to the fasting plasma concentrations of lipids and lipoproteins, no statistically significant differences were found for total cholesterol and LDLcholesterol, but TG and HDL-cholesterol were significantly increased after both 3 and 6 months' HRT. Accordingly, the LDLcholesterol to HDL-cholesterol ratio was significantly decreased after 3 and 6 months' HRT compared with the baseline value ( Table 1) .
Plasma adiponectin levels after 3 and 6 months of HRT were increased slightly, but the difference was not statistically significant ( Fig. 1) . Before treatment the PMW showed significantly lower adiponectin concentrations compared with the younger and older control groups (13.3 ± 6.7 µg/ml versus 15.7 ± 7.1 µg/ml and 16.3 ± 7.4 µg/ml, respectively). There was also no significant change in plasma leptin levels after 3 or 6 months' treatment ( Table 1) .
Plasma adiponectin levels in the PMW group before treatment were positively correlated with plasma HDL-cholesterol concentrations and were negatively correlated with BMI, body weight, TG level and 17β-oestradiol level ( Table 2 ). The correlation between the adiponectin concentrations and HDL-cholesterol or TG levels was also observed in the younger and older control groups ( Table 2) .
In contrast, circulating leptin levels were positively correlated with total cholesterol (r = 0.60 and P < 0.001 at 3 months; r = 0.30 and P < 0.05 at 6 months) and TG (r = 0.39 and P < 0.05 at 3 months; r = 0.65 and
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Discussion
In the present study, plasma leptin concentrations were positively correlated with total cholesterol and TG levels after 3 and 6 months' treatment with HRT in PMW, suggesting that circulating leptin may regulate lipid homeostasis during the continuous administration of combined oestrogen and progesterone. A positive correlation between lipid content and plasma leptin levels has also been recently reported in men; 9 in this investigation of 26 healthy men, plasma leptin concentrations were associated with TG levels after exercise.
In another study of 74 men, 9 it was also reported that plasma leptin concentrations were positively correlated with TG but not with HDL-cholesterol levels. Our data are compatible with the results of these studies, supporting the idea that plasma leptin concentrations may be associated with lipid metabolism in PMW receiving HRT. The amount and storage of fat and lipids in the body is controlled by both synthesis and degradation. Leptin has been reported to inhibit lipid synthesis and to regulate fatty acid metabolism in vitro, 10 suggesting that plasma leptin concentrations may change in response to alterations in fuel homeostasis. In humans, plasma adiponectin levels were associated with HDL concentrations and were inversely correlated with leptin levels. 8, 11 Our data support the idea that circulating adiponectin is also a homeostatic factor for energy storage in humans.
Hormone replacement therapy has been shown to improve impaired endotheliumdependent vasodilation of the brachial artery in healthy PMW 12 -14 and in PMW with hypertension. 12 Moreover, the Rancho Bernardo Study reported that HRT lowered systolic and diastolic blood pressures in PMW. 15 On the other hand, negative data concerning lipid changes and coronary heart H Sumino, T Takahashi, T Itoh et al.
Adiponectin levels during HRT disease events during hormone therapy have been reported in a recent prospective randomized trial. 2 Given the HRT-induced protection/repair of vascular endothelial cells and decrease in blood pressure, we hypothesized that HRT might influence the circulating level of adiponectin in PMW. In fact, in our study the plasma adiponectin levels were slightly increased after 3 and 6 months of HRT, but the difference was not statistically significant. Before HRT, PMW showed significantly lower adiponectin levels compared with younger or older women, and these levels were positively correlated with plasma HDL-cholesterol levels and negatively correlated with BMI and TG concentrations. These results suggest that circulating adiponectin may contribute to lipid homeostasis in PMW. This study has some limitations in that it was not randomized, double-blind and placebo-controlled in design, and the number of enrolled subjects was relatively small. Plasma adiponectin levels were not influenced by HRT in this study, but further studies are needed to elucidate the effect of HRT and oestrogen on adiponectin concentrations.
